Search - tctmd.com

Displaying 181 - 200 of 485

Sort: Relevancy | Date

Presentation TCT 2017

Lessons from the ABSORB Clinical Program for the Future

Presenter: Gary S. Mintz, Seung-Jung Park, Patrick W. Serruys

October 29, 2017

Presentation TCT 2017

Bioresorbable Scaffolds Are Here to Stay!

Presenter: Antonio Colombo, Stephen G. Ellis, Ron Waksman

October 29, 2017

Presentation TCT 2017

Flash Debate #3: Should BVS Scaffolds Be Used Today? No - The Evidence Says So!

Presenter: Jun-Jack Cheng, Kenneth Chin, Jack Wei Chieh Tan

October 29, 2017

Presentation TCT 2017

Flash Debate #3: Should BVS Scaffolds Be Used Today? Yes They Are Quite Safe With the Appropriate Implantation Strategy!

Presenter: Jun-Jack Cheng, Kenneth Chin, Teguh Santoso

October 29, 2017

Presentation TCT 2017

Current Updates on BVS: Asia-Pacific and Worldwide

Presenter: Jun-Jack Cheng, Kenneth Chin, Chiung Jen Wu

October 29, 2017

Presentation TCT 2017

Flash Debate #2: Is Shortening D2B Time Still Important in Primary PCI? No - Other Quality Metrics Are More Important!

Presenter: Jun-Jack Cheng, Kenneth Chin, Sreenivas Arramraju Kumar

October 29, 2017

Presentation TCT 2017

Flash Debate #2: Is Shortening D2B Time Still Important in Primary PCI? Yes- D2B Time Is an Index of Quality Care for STEMI!

Presenter: Jun-Jack Cheng, Kenneth Chin, Wei-Chun Huang

October 29, 2017

Presentation TCT 2017

PCI for STEMI With Cardiogenic Shock: Essential Management Strategies and Devices

Presenter: Jun-Jack Cheng, Kenneth Chin, Hsiu-Yu Fang

October 29, 2017

Presentation EuroPCR 2017

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Presenter: Runlin Gao

May 17, 2017

Presentation SCAI 2017

Long-term outcomes of Bioresorbable Vascular Scaffolds

Presenter: Roxana Mehran

May 13, 2017

Presentation ACC 2017

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Presenter: Stephen G. Ellis

March 19, 2017

Presentation JIM 2017

Bioresorbable Scaffolds is a Real Need:CONTRA

Presenter: Robert A. Byrne

February 10, 2017

Presentation JIM 2017

Bioresorbable Scaffolds: A Real Clinical Need? Yes!

Presenter: Gregg W. Stone

February 10, 2017

Presentation JIM 2017

Bioresorbable Scaffolds: An Important Clinical Need

Presenter: Gregg W. Stone

February 08, 2017

Presentation TCT 2016

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Fernando Alfonso

November 02, 2016

Presentation TCT 2016

How to Treat BRS Restenosis (With Case Examples)

Presenter: Ashok Seth, Pieter C. Smits

November 01, 2016

Presentation TCT 2016

How to Manage BRS Thrombosis (With Case Examples)

Presenter: Ashok Seth, Pieter C. Smits, Anuruck Jeamanukoolkit

November 01, 2016

Presentation TCT 2016

Identifying and Treating Benign Discontinuities From More Meaningful Intraluminal Scaffold Dismantling and Fractures (With Case Examples)

Presenter: Ashok Seth, Pieter C. Smits, Yoshinobu Onuma

November 01, 2016

Presentation TCT 2016

How to Manage BRS Stent Loss (With Case Examples)

Presenter: Ashok Seth, Pieter C. Smits, Omer Goktekin

November 01, 2016

Presentation TCT 2016

How to Overcome Challenges in Delivering BRS (With Case Examples)

Presenter: Ashok Seth, Pieter C. Smits

November 01, 2016

Advertisement

Lessons from the ABSORB Clinical Program for the Future

Bioresorbable Scaffolds Are Here to Stay!

Flash Debate #3: Should BVS Scaffolds Be Used Today? No - The Evidence Says So!

Flash Debate #3: Should BVS Scaffolds Be Used Today? Yes They Are Quite Safe With the Appropriate Implantation Strategy!

Current Updates on BVS: Asia-Pacific and Worldwide

Flash Debate #2: Is Shortening D2B Time Still Important in Primary PCI? No - Other Quality Metrics Are More Important!

Flash Debate #2: Is Shortening D2B Time Still Important in Primary PCI? Yes- D2B Time Is an Index of Quality Care for STEMI!

PCI for STEMI With Cardiogenic Shock: Essential Management Strategies and Devices

Randomized Comparison of Everolimus-eluting Bioresorbable Vascular Scaffolds vs. Everolimus-eluting Metallic Stents in Patients with Coronary Artery Disease: 3-year Clinical Outcomes from ABSORB China

Long-term outcomes of Bioresorbable Vascular Scaffolds

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results

Bioresorbable Scaffolds is a Real Need:CONTRA

Bioresorbable Scaffolds: A Real Clinical Need? Yes!

Bioresorbable Scaffolds: An Important Clinical Need

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

How to Treat BRS Restenosis (With Case Examples)

How to Manage BRS Thrombosis (With Case Examples)

Identifying and Treating Benign Discontinuities From More Meaningful Intraluminal Scaffold Dismantling and Fractures (With Case Examples)

How to Manage BRS Stent Loss (With Case Examples)

How to Overcome Challenges in Delivering BRS (With Case Examples)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content